The General Assembly of LZVO approved the annual flat fee for MAHs

On November 30, 2022, a General Assembly meeting of stakeholders of the Latvian Medicines Verification Organisation (LZVO) was held, where the strategy and budget for 2023 were approved.

The General Assembly also approved the fixed annual flat fee for the year 2023 for the marketing authorisation holders (MAHs), including parallel importers and parallel distributors of medicines in the territory of Latvia, in accordance with the financing policy for the maintenance and development of the Latvian Medicines Verification System. The fixed flat fee per each MAH set by the General Assembly for the next year is 3,000 euros.

In case of questions about the annual flat fee or other current events MAH representatives are welcomed to contact LZVO by writing to 

The Association “Latvian Medicines Verification Organisation” (LZVO) was established in December 2016 with the aim to establish, maintain and manage the Latvian Medicines Verification System in accordance with the requirements of the European Medicines Verification System, the Falsified Medicines Directive, and the Delegated Regulation. The founders of the association are professional associations of medicines manufacturers, wholesalers, pharmacies, and other industries involved in the circulation of medicines: Association of International Research-based Pharmaceuticals Manufacturers, The Latvian Generic Medicines Association, the Latvian National Medicines Supply Association, the Latvian Association of Pharmaceutical Care, and the Latvian Medicines Parallel Import Association.